Literature DB >> 21037559

Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?

Manuel Ramos-Casals1.   

Abstract

Immunosuppression has been associated with viral reactivation in patients with chronic viral infections. a prospective study has concluded that it is safe to use anti-tumor-necrosis-factor agents in patients with chronic hepatitis B virus infection receiving antiviral prophylaxis. Is there sufficient evidence to back up this conclusion?

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21037559     DOI： 10.1038/nrrheum.2010.156

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.

Authors:  R Caporali; F Bobbio-Pallavicini; F Atzeni; G Sakellariou; M Caprioli; C Montecucco; P Sarzi-Puttini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

Review 2.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

3.  Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

Authors:  Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

Review 4.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

Review 5.  Prevention and management of drug resistance for antihepatitis B treatment.

Authors:  Man-Fung Yuen; James Fung; Danny Ka-Ho Wong; Ching-Lung Lai
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

6.  Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Authors:  D Vassilopoulos; A Apostolopoulou; E Hadziyannis; G V Papatheodoridis; S Manolakopoulos; J Koskinas; E K Manesis; A I Archimandritis
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

Review 7.  Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach.

Authors:  Debbie M Nathan; Peter W Angus; Peter R Gibson
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

Review 8.  Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B.

Authors:  Xavier Verhelst; Hans Orlent; Isabelle Colle; Anja Geerts; Martine De Vos; Hans Van Vlierberghe
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-04       Impact factor: 2.566

9.  Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

Authors:  Marc Michel; Cristophe Duvoux; Cristophe Hezode; Daniel Cherqui
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

10.  Reactivation of hepatitis B.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425
  10 in total
  1 in total

1.  Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease.

Authors:  Cristián Navarrete-Dechent; Daniela Majerson; Marisa Torres; Daniela Armijo; Mahir Patel; Alan Menter; Claudia de la Cruz
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.